T
Thomas Laughren
Researcher at Food and Drug Administration
Publications - 34
Citations - 5507
Thomas Laughren is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Clinical trial & Major depressive disorder. The author has an hindex of 21, co-authored 34 publications receiving 5227 citations. Previous affiliations of Thomas Laughren include Center for Drug Evaluation and Research.
Papers
More filters
Journal ArticleDOI
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Response to consensus statement
TL;DR: The ADA concluded that aripiprazole and ziprasidone have no effect on the risk of diabetes, solely based on data from clinical trials that did not include these two drugs in epidemiological studies.
Journal ArticleDOI
Mood disorders in the medically ill: scientific review and recommendations.
Dwight L. Evans,Dennis S. Charney,Dennis S. Charney,Lydia Lewis,Robert N. Golden,Jack M. Gorman,K. Ranga Rama Krishnan,Charles B. Nemeroff,J. Douglas Bremner,Robert M. Carney,James C. Coyne,Mahlon R. DeLong,Nancy Frasure-Smith,Alexander H. Glassman,Philip W. Gold,Igor Grant,Lisa P. Gwyther,Gail Ironson,Robert L. Johnson,Andres M. Kanner,Wayne Katon,Peter G. Kaufmann,Francis J. Keefe,Terence A. Ketter,Thomas Laughren,Jane Leserman,Constantine G. Lyketsos,William M. McDonald,Bruce S. McEwen,Andrew H. Miller,Dominique L. Musselman,Christopher M. O'Connor,John M. Petitto,Bruce G. Pollock,Robert G. Robinson,Steven P. Roose,Julia H. Rowland,Yvette I. Sheline,David S. Sheps,Gregory E. Simon,David Spiegel,Albert J. Stunkard,Trey Sunderland,Paul Tibbits,William J. Valvo +44 more
TL;DR: A growing body of evidence suggests that biological mechanisms underlie a bidirectional link between mood disorders and many medical illnesses and there is evidence to suggest that mood disorders affect the course of medical illnesses.
Journal ArticleDOI
Suicidality in pediatric patients treated with antidepressant drugs.
TL;DR: Use of antidepressant drugs in pediatric patients is associated with a modestly increased risk of suicidality, and a meta-analysis was conducted to obtain overall suicidity risk estimates.
Journal ArticleDOI
Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
Marc Stone,Thomas Laughren,M Lisa Jones,Mark Levenson,P Chris Holland,Alice Hughes,Tarek A. Hammad,Robert Temple,George Rochester +8 more
TL;DR: The net effect seems to be neutral on suicidal behaviour but possibly protective for suicidal ideation in adults aged 25-64 and to reduce the risk of both suicidality and suicidal behaviour in those aged ≥65.
Journal ArticleDOI
A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia
Robert W. Buchanan,Miriam Davis,Donald C. Goff,Michael F. Green,Richard S.E. Keefe,Andrew C. Leon,Keith H. Nuechterlein,Thomas Laughren,Robert L. Levin,Ellen Stover,Wayne S. Fenton,Steve Marder +11 more
TL;DR: The suggested guidelines represent reasonable starting points for trial design of cognitive-enhancing drugs, with the understanding that new data, subsequent findings, or other methodological considerations may lead to future modifications.